NeuroPace to Participate in Upcoming Healthcare Conferences in September
NeuroPace (Nasdaq: NPCE), a medical device company focused on epilepsy treatment, has announced its participation in two major healthcare conferences this September.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NeuroPace (Nasdaq: NPCE), a medical device company focused on epilepsy treatment, has announced its participation in two major healthcare conferences this September. The company will:
- Attend the Wells Fargo 2024 Healthcare Conference on September 4 in Boston, hosting one-on-one investor meetings
- Present at the Morgan Stanley 22nd Annual Global Healthcare Conference from September 4-6 in New York
At the Morgan Stanley conference, CEO Joel Becker and CFO Rebecca Kuhn will participate in a fireside chat on September 6 at 8:30am ET, which will be webcast live. They will also host one-on-one investor meetings. A replay of the fireside chat will be available on NeuroPace's Investor website.
Details
News Market Reaction – NPCE
The recorded move for NPCE in the trading session of this news was +12.98%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MOUNTAIN VIEW, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will participate in two healthcare conferences in September. NeuroPace management will host one-on-one meetings with investors at the Wells Fargo 2024 Healthcare Conference, on Wednesday, September 4 in Boston, MA.
NeuroPace will also present at the Morgan Stanley 22nd Annual Global Healthcare Conference, which takes place September 4-6, in New York, NY. Joel Becker, Chief Executive Officer, and Rebecca Kuhn, Chief Financial Officer, will participate in a fireside chat discussion on Friday, September 6 at 8:30am ET, and host one-on-one meetings with investors during the conference. The fireside chat will be accessible via a live webcast here and a replay will be available in the Events section of NeuroPace’s Investor website at https://investors.neuropace.com/news-and-events/events.
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
Investor Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
jfeffer@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.